Plus Therapeutics Stock Price on December 4, 2024
| PSTV Stock | USD 1.31 0.04 2.96% |
Below is the normalized historical share price chart for Plus Therapeutics extending back to July 11, 2001. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Plus Therapeutics stands at 1.31, as last reported on the 11th of December 2024, with the highest price reaching 1.31 and the lowest price hitting 1.31 during the day.
If you're considering investing in Plus Stock, it is important to understand the factors that can impact its price. At this stage we consider Plus Stock to be unstable. Plus Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of 0.0012, which implies the firm had a 0.0012% return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Plus Therapeutics, which you can use to evaluate the volatility of the company. Please check Plus Therapeutics' Coefficient Of Variation of 2125.7, semi deviation of 5.31, and Risk Adjusted Performance of 0.0426 to confirm if the risk estimate we provide is consistent with the expected return of 0.0067%.
At this time, Plus Therapeutics' Common Stock Shares Outstanding is fairly stable compared to the past year. Preferred Stock And Other Adjustments is likely to climb to about 893 K in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 10.8 M in 2024. . Price To Sales Ratio is likely to drop to 1.06 in 2024. Price Earnings Ratio is likely to drop to -0.43 in 2024. Plus Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 16th of November 2000 | 200 Day MA 1.669 | 50 Day MA 1.3236 | Beta 0.69 |
Plus |
Sharpe Ratio = 0.0012
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PSTV |
Estimated Market Risk
| 5.35 actual daily | 47 53% of assets are more volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Plus Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Plus Therapeutics by adding Plus Therapeutics to a well-diversified portfolio.
Price Book 3.7603 | Enterprise Value Ebitda (0.30) | Price Sales 1.4449 | Shares Float 5.7 M | Wall Street Target Price 15.75 |
Plus Therapeutics Main Headline on 4th of December 2024
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Dat... by finance.yahoo.com
Company to present ReSPECT-LM Phase 1 trial data on Rhenium Obisbemeda with a focus on treating leptomeningeal metastases in breast cancer patients AUSTIN, Texas, Dec. 04, 2024 -- Plus Therapeutics, Inc. , a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, will present data at the 2024 San Antonio Breast Cancer Symposium, D
Plus Therapeutics Valuation on December 4, 2024
It is possible to determine the worth of Plus Therapeutics on a given historical date. On December 4, 2024 Plus was worth 1.33 at the beginning of the trading date compared to the closed value of 1.33. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Plus Therapeutics stock. Still, in general, we apply an absolute valuation method to find Plus Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Plus Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Plus Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 1.30 | 1.42 | 1.30 | 1.34 | 122,749 | |
12/04/2024 | 1.33 | 1.37 | 1.32 | 1.33 | 26,548 |
| 1.36 | 1.40 | 1.31 | 1.34 | 87,413 |
| Backtest Plus Therapeutics | | | Plus Therapeutics History | | | Plus Therapeutics Valuation | Previous | Next |
Plus Therapeutics Trading Date Momentum on December 4, 2024
| On December 05 2024 Plus Therapeutics was traded for 1.34 at the closing time. The top price for the day was 1.40 and the lowest listed price was 1.31 . The trading volume for the day was 87.4 K. The trading history from December 5, 2024 was a factor to the next trading day price increase. The trading delta at closing time against the next closing price was 0.75% . The trading delta at closing time against the current closing price is 1.50% . |
Plus Therapeutics Fundamentals Correlations and Trends
By evaluating Plus Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Plus Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Plus financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Plus Therapeutics Stock history
Plus Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Plus is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Plus Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Plus Therapeutics stock prices may prove useful in developing a viable investing in Plus Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 3.1 M | 3.3 M | |
| Net Loss | -23.3 M | -24.5 M |
Plus Therapeutics Stock Technical Analysis
Plus Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Plus Therapeutics Period Price Range
Low | December 11, 2024
| High |
0.00 | 0.00 |
Plus Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Plus Therapeutics December 11, 2024 Market Strength
Market strength indicators help investors to evaluate how Plus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Plus Therapeutics shares will generate the highest return on investment. By undertsting and applying Plus Therapeutics stock market strength indicators, traders can identify Plus Therapeutics entry and exit signals to maximize returns
Plus Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Plus Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Plus Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Plus to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0426 | |||
| Jensen Alpha | 0.1578 | |||
| Total Risk Alpha | (0.61) | |||
| Sortino Ratio | 0.0207 | |||
| Treynor Ratio | 0.3234 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.